Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Storek, J.
Right arrow Articles by Appelbaum, F. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Storek, J.
Right arrow Articles by Appelbaum, F. R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

RAPID COMMUNICATION


Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease

Jan Storek, Ted Gooley, Muriel Siadak, William I. Bensinger, David G. Maloney, Thomas R. Chauncey, Mary Flowers, Keith M. Sullivan, Robert P. Witherspoon, Scott D. Rowley, John A. Hansen, Rainer Storb, and Frederick R. Appelbaum

From the Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, WA.

Chronic graft-versus-host disease (GVHD) is likely caused by donor T lymphocytes. Because unmodified blood stem cell grafts contain one log more T lymphocytes than unmodified marrow grafts, we evaluated the incidence of chronic GVHD in previously reported 37 blood stem cell recipients and 37 computer-matched historical control marrow recipients (Bensinger et al, Blood 88:2794, 1996). All patients have been followed until death, relapse, or occurrence of chronic GVHD or for a minimum of 2 years. In a univariable proportional hazards regression model, the relative risk of developing clinical chronic GVHD (includes clinical limited and clinical extensive disease) by 2 years posttransplant among the peripheral blood stem cell recipients compared with the marrow recipients was 2.22 (95% confidence interval, 1.04 to 4.74; P = .039). For clinical extensive chronic GVHD, the relative risk was 2.37 (95% confidence interval, 1.07 to 5.29; P = .035). In multivariable analyses, considering also the covariables of patient age, patient cytomegalovirus serostatus, and donor cytomegalovirus serostatus, the relative risks of clinical chronic GVHD and clinical extensive chronic GVHD were also greater than 2 (P < .05). We conclude that the transplantation of unmanipulated filgrastim-mobilized blood stem cells may result in a relatively high incidence of chronic GVHD.

Blood, Vol. 90 No. 12 (December 15), 1997: pp. 4705-4709
© 1997 by The American Society of Hematology.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
H. Frangoul, E. R. Nemecek, D. Billheimer, M. A. Pulsipher, S. Khan, A. Woolfrey, B. Manes, C. Cole, M. C. Walters, M. Ayas, et al.
A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study
Blood, December 15, 2007; 110(13): 4584 - 4587.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. H. C. Baumeister, K. Holig, M. Bornhauser, M. Meurer, E. P. Rieber, and K. Schakel
G-CSF mobilizes slanDCs (6-sulfo LacNAc+ dendritic cells) with a high proinflammatory capacity
Blood, October 15, 2007; 110(8): 3078 - 3081.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Rutella, F. Zavala, S. Danese, H. Kared, and G. Leone
Granulocyte Colony-Stimulating Factor: A Novel Mediator of T Cell Tolerance
J. Immunol., December 1, 2005; 175(11): 7085 - 7091.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Banovic, K. P. A. MacDonald, E. S. Morris, V. Rowe, R. Kuns, A. Don, J. Kelly, S. Ledbetter, A. D. Clouston, and G. R. Hill
TGF-{beta} in allogeneic stem cell transplantation: friend or foe?
Blood, September 15, 2005; 106(6): 2206 - 2214.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
L. H. S. Tomas, F. R. Loberiza Jr, J. P. Klein, P. M. Layde, R. J. Lipchik, J. D. Rizzo, C. N. Bredeson, and M. M. Horowitz
Risk Factors for Bronchiolitis Obliterans in Allogeneic Hematopoietic Stem-Cell Transplantation for Leukemia
Chest, July 1, 2005; 128(1): 153 - 161.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Eapen, M. M. Horowitz, J. P. Klein, R. E. Champlin, F. R. Loberiza Jr, O. Ringden, and J. E. Wagner
Higher Mortality After Allogeneic Peripheral-Blood Transplantation Compared With Bone Marrow in Children and Adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry
J. Clin. Oncol., December 15, 2004; 22(24): 4872 - 4880.
[Abstract] [Full Text] [PDF]


Home page
JDRHome page
R.M. Nagler and A. Nagler
The Molecular Basis of Salivary Gland Involvement in Graft-vs.-Host Disease
Journal of Dental Research, February 1, 2004; 83(2): 98 - 103.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Franzke, W. Piao, J. Lauber, P. Gatzlaff, C. Konecke, W. Hansen, A. Schmitt-Thomsen, B. Hertenstein, J. Buer, and A. Ganser
G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases
Blood, July 15, 2003; 102(2): 734 - 739.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
O. Ringden, M. Labopin, A. Bacigalupo, W. Arcese, U.W. Schaefer, R. Willemze, H. Koc, D. Bunjes, E. Gluckman, V. Rocha, et al.
Transplantation of Peripheral Blood Stem Cells as Compared With Bone Marrow From HLA-Identical Siblings in Adult Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
J. Clin. Oncol., December 15, 2002; 20(24): 4655 - 4664.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Yamamoto, B. Wang, S. Fukuhara, S. Ikehara, and R. A. Good
Mixed peripheral blood stem cell transplantation for autoimmune disease in BXSB/MpJ mice
Blood, August 13, 2002; 100(5): 1886 - 1893.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Couban, D. R. Simpson, M. J. Barnett, C. Bredeson, L. Hubesch, K. Howson-Jan, T. B. Shore, I. R. Walker, P. Browett, H. A. Messner, et al.
A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies
Blood, August 13, 2002; 100(5): 1525 - 1531.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. J. Lee, J. P. Klein, A. J. Barrett, O. Ringden, J. H. Antin, J.-Y. Cahn, M. H. Carabasi, R. P. Gale, S. Giralt, G. A. Hale, et al.
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse
Blood, June 28, 2002; 100(2): 406 - 414.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Guardiola, V. Runde, A. Bacigalupo, T. Ruutu, F. Locatelli, M. A. Boogaerts, A. Pagliuca, J. J. Cornelissen, H. C. Schouten, E. Carreras, et al.
Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes
Blood, May 29, 2002; 99(12): 4370 - 4378.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Mehta, S. Singhal, C. Cutler, and J. H. Antin
Chronic Graft-Versus-Host Disease After Allogeneic Peripheral-Blood Stem-Cell Transplantation: A Little Methotrexate Goes a Long Way
J. Clin. Oncol., January 15, 2002; 20(2): 603 - 606.
[Full Text] [PDF]


Home page
BloodHome page
J. Morton, C. Hutchins, and S. Durrant
Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells
Blood, December 1, 2001; 98(12): 3186 - 3191.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Przepiorka, P. Anderlini, R. Saliba, K. Cleary, R. Mehra, I. Khouri, Y. O. Huh, S. Giralt, I. Braunschweig, K. van Besien, et al.
Chronic graft-versus-host disease after allogeneic blood stem cell transplantation
Blood, September 15, 2001; 98(6): 1695 - 1700.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Remberger, O. Ringden, I.-W. Blau, H. Ottinger, B. Kremens, M. G. Kiehl, J. Aschan, D. W. Beelen, N. Basara, G. Kumlien, et al.
No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors
Blood, September 15, 2001; 98(6): 1739 - 1745.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. Cutler, S. Giri, S. Jeyapalan, D. Paniagua, A. Viswanathan, and J. H. Antin
Acute and Chronic Graft-Versus-Host Disease After Allogeneic Peripheral-Blood Stem-Cell and Bone Marrow Transplantation: A Meta-Analysis
J. Clin. Oncol., August 15, 2001; 19(16): 3685 - 3691.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. D. Rowley, G. Donaldson, K. Lilleby, W. I. Bensinger, and F. R. Appelbaum
Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation
Blood, May 1, 2001; 97(9): 2541 - 2548.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
V. Lapierre, N. Oubouzar, A. Auperin, D. Tramalloni, H. Tayebi, E. Robinet, M. Kuentz, D. Blaise, O. Hartmann, P. Herve, et al.
Influence of the hematopoietic stem cell source on early immunohematologic reconstitution after allogeneic transplantation
Blood, May 1, 2001; 97(9): 2580 - 2586.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
W. I. Bensinger, P. J. Martin, B. Storer, R. Clift, S. J. Forman, R. Negrin, A. Kashyap, M. E.D. Flowers, K. Lilleby, T. R. Chauncey, et al.
Transplantation of Bone Marrow as Compared with Peripheral-Blood Cells from HLA-Identical Relatives in Patients with Hematologic Cancers
N. Engl. J. Med., January 18, 2001; 344(3): 175 - 181.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
H. Matsubara, A. Makimoto, J. Takayama, T. Higa, T. Saito, Y. Kanda, R. Tanosaki, S. Mineishi, M. Ohira, and Y. Takaue
Possible Clinical Benefits of the Use of Peripheral Blood Stem Cells Over Bone Marrow in the Allogeneic Transplantation Setting for the Treatment of Childhood Leukemia
Jpn. J. Clin. Oncol., January 1, 2001; 31(1): 30 - 34.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
H. Ozer, J. O. Armitage, C. L. Bennett, J. Crawford, G. D. Demetri, P. A. Pizzo, C. A. Schiffer, T. J. Smith, G. Somlo, J. C. Wade, et al.
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines
J. Clin. Oncol., October 20, 2000; 18(20): 3558 - 3585.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
V. Ratanatharathorn, E. Carson, C. Reynolds, L. J. Ayash, J. Levine, G. Yanik, S. M. Silver, J. L.M. Ferrara, and J. P. Uberti
Anti-CD20 Chimeric Monoclonal Antibody Treatment of Refractory Immune-Mediated Thrombocytopenia in a Patient with Chronic Graft-versus-Host Disease
Ann Intern Med, August 15, 2000; 133(4): 275 - 279.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. E. Champlin, N. Schmitz, M. M. Horowitz, B. Chapuis, R. Chopra, J. J. Cornelissen, R. P. Gale, J. M. Goldman, F. R. Loberiza Jr, B. Hertenstein, et al.
Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation
Blood, June 15, 2000; 95(12): 3702 - 3709.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Arpinati, C. L. Green, S. Heimfeld, J. E. Heuser, and C. Anasetti
Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells
Blood, April 15, 2000; 95(8): 2484 - 2490.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Siena, R. Schiavo, P. Pedrazzoli, and C. Carlo-Stella
Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy
J. Clin. Oncol., March 13, 2000; 18(6): 1360 - 1377.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. Blaise, M. Kuentz, C. Fortanier, J. H. Bourhis, N. Milpied, L. Sutton, J.-P. Jouet, M. Attal, P. Bordigoni, J.-Y. Cahn, et al.
Randomized Trial of Bone Marrow Versus Lenograstim-Primed Blood Cell Allogeneic Transplantation in Patients With Early-Stage Leukemia: A Report From the Societe Francaise de Greffe de Moelle
J. Clin. Oncol., February 1, 2000; 18(3): 537 - 537.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. R. Appelbaum
Choosing the Source of Stem Cells for Allogeneic Transplantation: No Longer a Peripheral Issue
Blood, July 15, 1999; 94(2): 381 - 383.
[Full Text] [PDF]


Home page
BloodHome page
O. Ringden, M. Remberger, V. Runde, M. Bornhauser, I.W. Blau, N. Basara, K. Holig, D.W. Beelen, H. Hagglund, O. Basu, et al.
Peripheral Blood Stem Cell Transplantation From Unrelated Donors: A Comparison With Marrow Transplantation
Blood, July 15, 1999; 94(2): 455 - 464.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Engelhardt, H. Bertz, M. Afting, C. F. Waller, and J. Finke
High- Versus Standard-Dose Filgrastim (rhG-CSF) for Mobilization of Peripheral-Blood Progenitor Cells From Allogeneic Donors and CD34+ Immunoselection
J. Clin. Oncol., July 1, 1999; 17(7): 2160 - 2160.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Pan, T. Teshima, G. R. Hill, D. Bungard, Y. S. Brinson, V. S. Reddy, K. R. Cooke, and J. L.M. Ferrara
Granulocyte Colony-Stimulating Factor-Mobilized Allogeneic Stem Cell Transplantation Maintains Graft-Versus-Leukemia Effects Through a Perforin-Dependent Pathway While Preventing Graft-Versus-Host Disease
Blood, June 15, 1999; 93(12): 4071 - 4078.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
R. K. Burt
Clinical Utility in Maximizing CD34+ Cell Count in Stem Cell Grafts
Oncologist, June 1, 1999; 4(3): 265 - 268.
[Full Text]


Home page
BloodHome page
M. N. Yenerel, D. Sargin, and Y. Tangun
High Risk of Chronic Graft-Versus-Host Disease in Unmanipulated Allogeneic Peripheral Blood Stem Cell Transplantation
Blood, October 15, 1998; 92(8): 2973 - 2975.
[Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1997 by American Society of Hematology         Online ISSN: 1528-0020